Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Cash & Equivalents (2019 - 2025)

Avidity Biosciences' Cash & Equivalents history spans 7 years, with the latest figure at $382.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 73.97% year-over-year to $382.5 million; the TTM value through Dec 2025 reached $382.5 million, up 73.97%, while the annual FY2025 figure was $382.5 million, 73.97% up from the prior year.
  • Cash & Equivalents reached $382.5 million in Q4 2025 per RNA's latest filing, up from $350.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $575.8 million in Q2 2024 to a low of $85.6 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $273.4 million, with a median of $265.3 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: tumbled 64.95% in 2022, then skyrocketed 332.21% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $320.4 million in 2021, then grew by 6.23% to $340.4 million in 2022, then tumbled by 45.63% to $185.1 million in 2023, then increased by 18.79% to $219.9 million in 2024, then surged by 73.97% to $382.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Cash & Equivalents are $382.5 million (Q4 2025), $350.2 million (Q3 2025), and $243.9 million (Q2 2025).